Aug 2, 2017

LAS VEGAS, August 2, 2017/PR Newswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is proud to announce an agreement with the Los Coyotes Band of Cahuilla and Cupeno Indians (Los Coyotes) for the purposes of establishing cannabis operations on the tribe’s lands located near Warner Springs, California.

The nonbinding Joint Statement of Intent outlines plans to build and operate facilities to grow, manufacture, and distribute commercial cannabis and cannabis products in the State of California.  

This is the first time a publicly traded US cannabis cultivation company and a federally recognized Native American tribe have announced a commercial cannabis venture in California.

GB Sciences will construct facilities on designated areas of tribal land for the business of cultivation, manufacturing and other commercial cannabis activities. Los Coyotes will receive 40 percent of the venture’s net profits, of which 10 percent will fund tribal childhood education and elder assistance programs. 

GB Sciences John Poss said, “The tribe and its leadership are ideal partners for GB Sciences. We share the same attitudes toward the business, the same intentions for the quality of the product, and the same positive goals for tribe. It is difficult to imagine a better way to enter the gigantic California cannabis market.”

Los Coyotes Tribal Chairman Shane Chapparosa said, “We welcome this important partnership with GB Sciences. They are the ideal partners to facilitate Los Coyotes’ move into California’s cannabis market. In addition to producing much-needed revenue and jobs for the tribe, the partnership will confer a distinct benefit to patients as we work with GB to develop strains with great therapeutic value.”

The Statement is subject to definitive agreements between the parties to be completed and executed in the near future. Once consummated, the agreement between the Tribe and GB will result in a new entity, which would be initially funded by advances from GB, and which ultimately would be owned 60 percent by GB Sciences and 40 percent by the tribe, with GB being the manager of the operation.

The Statement also makes it clear that all applicable rules and regulations will be respected by both parties, and that appropriate, applicable licensure pursuant to, or replicating, the Medicinal and Adult Use Cannabis Regulation and Safety Act will be sought. Further, the Statement is clear that no steps will be taken that could possibly compromise or abrogate the Tribe’s sovereign status.  

About GB Sciences, Inc.

GB Sciences, Inc. (GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.  

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information

Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or 

Liz Bianco Publicity Director, liz@gbsciences.com, http://gbsciences.com

Tom Arcuragi, COO, tom@gbsciences.com